Adam M. Weidner

Array ( [id] => 14896965 [patent_doc_number] => 20190292248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/358935 [patent_app_country] => US [patent_app_date] => 2019-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49609 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14868777 [patent_doc_number] => 20190284630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => RETINAL GANGLION CELL SUBTYPE DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS [patent_app_type] => utility [patent_app_number] => 16/354888 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16354888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15540859 [patent_doc_number] => 10570195 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-02-25 [patent_title] => Conformation-independent antibodies against neurotoxic tau proteins [patent_app_type] => utility [patent_app_number] => 16/297815 [patent_app_country] => US [patent_app_date] => 2019-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 6366 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16297815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14464661 [patent_doc_number] => 20190183970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING HUNTINGTON'S DISEASE [patent_app_type] => utility [patent_app_number] => 16/291708 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27816 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291708 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14810201 [patent_doc_number] => 20190271710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-05 [patent_title] => ASSAYS TO DETECT NEURODEGENERATION [patent_app_type] => utility [patent_app_number] => 16/291264 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27607 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541020 [patent_doc_number] => 20200407433 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONIST ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/975120 [patent_app_country] => US [patent_app_date] => 2019-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35051 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16975120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18071436 [patent_doc_number] => 11530259 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-20 [patent_title] => Therapies and methods to treat TLR2-mediated diseases and disorders [patent_app_type] => utility [patent_app_number] => 16/965271 [patent_app_country] => US [patent_app_date] => 2019-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 32 [patent_no_of_words] => 18619 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16572909 [patent_doc_number] => 10894822 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-19 [patent_title] => Treatment of tauopathies [patent_app_type] => utility [patent_app_number] => 16/259167 [patent_app_country] => US [patent_app_date] => 2019-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 38408 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 114 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16259167 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14341883 [patent_doc_number] => 20190152914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => NMDA ANTAGONIST PRODRUGS [patent_app_type] => utility [patent_app_number] => 16/252648 [patent_app_country] => US [patent_app_date] => 2019-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16252648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16125995 [patent_doc_number] => 10696739 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-30 [patent_title] => Anti-tau antibodies [patent_app_type] => utility [patent_app_number] => 16/250733 [patent_app_country] => US [patent_app_date] => 2019-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 18917 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16250733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17074904 [patent_doc_number] => 11111289 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-07 [patent_title] => Anti-CGRP compositions and use thereof [patent_app_type] => utility [patent_app_number] => 16/248284 [patent_app_country] => US [patent_app_date] => 2019-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 74 [patent_figures_cnt] => 46 [patent_no_of_words] => 48704 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16248284 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17713504 [patent_doc_number] => 11377487 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-05 [patent_title] => Factor H potentiating antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/961737 [patent_app_country] => US [patent_app_date] => 2019-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 4 [patent_no_of_words] => 22014 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 172 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16961737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15395819 [patent_doc_number] => 10538553 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-21 [patent_title] => Compounds for the treatment of neurodegenerative diseases [patent_app_type] => utility [patent_app_number] => 16/240673 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 14265 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16240673 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17369971 [patent_doc_number] => 20220025023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => MISFOLDED TDP-43 BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 16/959385 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42219 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16959385 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711942 [patent_doc_number] => 20210079089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => ANTI-LRP5/6 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/954483 [patent_app_country] => US [patent_app_date] => 2018-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16954483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16504833 [patent_doc_number] => 20200384089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => PURIFIED ARYLSULFATASE A AND COMPOSITONS THEREOF [patent_app_type] => utility [patent_app_number] => 16/955644 [patent_app_country] => US [patent_app_date] => 2018-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40886 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -64 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16955644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762390 [patent_doc_number] => 20210107971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => ANTI-ALPHA-SYNUCLEIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/771993 [patent_app_country] => US [patent_app_date] => 2018-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35471 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16771993 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16749955 [patent_doc_number] => 20210101964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => ANTI-ALPHA SYNUCLEIN ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/772043 [patent_app_country] => US [patent_app_date] => 2018-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27634 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16772043 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16533324 [patent_doc_number] => 10875908 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-29 [patent_title] => Antibody binding a linear epitope of human p53 and diagnostic applications thereof [patent_app_type] => utility [patent_app_number] => 16/214455 [patent_app_country] => US [patent_app_date] => 2018-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 1888 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16214455 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17768249 [patent_doc_number] => 11400168 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-02 [patent_title] => Methods and systems for noninvasive control of brain cells and related vectors and compositions [patent_app_type] => utility [patent_app_number] => 16/213991 [patent_app_country] => US [patent_app_date] => 2018-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 30032 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 471 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16213991 [rel_patent_id] =>[rel_patent_doc_number] =>)